Eli Lilly’s Blockbuster Drug Growth in Q3 2023
N ews (3)
N ews (3)
In the third quarter of 2023, Eli Lilly and Company reported revenue of $9.5 billion, a remarkable 37% year-over-year increase, driven by blockbuster drugs like Mounjaro and Zepbound in the diabetes and obesity markets. Net income reached $2.1 billion, reflecting strong demand and pricing power. Mounjaro, a GLP-1 receptor agonist, generated $1.4 billion in sales, capturing 20% of the U.S. diabetes market and positioning Lilly as a leader in the $100 billion obesity treatment space. The company’s pipeline, including phase 3 trials for new indications, supports projected revenue growth of 25% annually through 2027, with oncology and Alzheimer’s drugs adding diversification.
Fund Rotation Signals Overvaluation
The Saudi sovereign fund’s focus on Unit....
Insider Buying Signals Pipeline Confidence
Insider buying of $4 million, including $1 million by the CEO
Analyst Upgrades Boost Outlook
A positive deal with a $125 target from Raymond
Novo’s Value Outshines Lilly
Novo Nordisk’s 52-week lows at $67 reflect fears.....
Healthcare’s Undervalued Opportunity
Healthcare is the most undervalued sector, with insider buying
Supply Constraints Favor Competitors
Novo’s P/E below its 10-year average and strong
Insider Buying Signals Pipeline Confidence
Insider buying of $4 million, including $1 million by the CEO
Analyst Upgrades Boost Outlook
A positive deal with a $125 target from Raymond
Healthcare’s Undervalued Opportunity
Healthcare is the most undervalued sector, with insider buying
Fund Rotation Signals Overvaluation
The Saudi sovereign fund’s focus on Unit....
Novo’s Value Outshines Lilly
Novo Nordisk’s 52-week lows at $67 reflect fears.....
Supply Constraints Favor Competitors
Novo’s P/E below its 10-year average and strong







